Interestingly, it was reported that Ganoderma lucidum exhibited anti-obesity activity by down-regulating FAS, SCD1, and SREBP1c, and also displayed antihyperglycemic and antihyperinsulinemic activities by enhancing the activation of AMP-activated protein kinase (AMPK), ACC, insulin receptor, insulin-receptor substrate, and protein kinase B. AMPK activation attenuates the transcription and translation of lipogenic genes such as FAS and SCD1 and increases ACC protein expression [32]. The gene discussed is SREBF1; the disease is obesity due to melanocortin 4 receptor deficiency.